NMDA receptor pathways as drug targets (Q34982270)

5 August 2017

1 reference

title

NMDA receptor pathways as drug targets (English)

1 reference

5 August 2017

John A Kemp

1

1 reference

5 August 2017

Ruth M McKernan

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

5 Suppl

1 reference

5 August 2017

page(s)

1039-1042

1 reference

N-methyl-D-aspartic acid receptor structure and function

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

NMDA receptors as targets for drug action in neuropathic pain.

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

NMDA receptor antagonists as analgesics: focus on the NR2B subtype

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Glycine-site antagonists and stroke

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Facilitation of social learning by treatment with an NMDA receptor antagonist.

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

NMDA receptor antagonists can enhance or impair learning performance in animals.

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Glutamatergic mechanisms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Schizophrenia and glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Genetic enhancement of learning and memory in mice

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Proteomic analysis of NMDA receptor-adhesion protein signaling complexes

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.

1 reference

https://api.crossref.org/works/10.1038%2FNN936

7 January 2021

Identifiers

DOI

10.1038/NN936

1 reference

Dimensions Publication ID

5 August 2017

1016862545

0 references

1 reference